L-Ornithine-L-Aspartate and Intermittent Renal Replacement Therapy in Fulminant Hepatitis A: A Case Report
Abstract
Hepatitis A is a common viral infection worldwide that is transmitted via the fecal-oral route. Since the introduction of an efficient vaccine, the incidence of infection has decreased but the number of cases has risen due to widespread community outbreaks among unimmunized individuals. Classic symptoms include fever, malaise, dark urine, and jaundice, and are more common in older children and adults. People are often most infectious 14 days prior to and 7 days following the onset of jaundice. We will discuss the case of a young male patient, diagnosed with acute hepatitis A, leading to fulminant hepatitis refractory to conventional therapy and the development of subsequent kidney injury. The medical treatment through the course of hospitalization was challenging and included the use of L-ornithine-L-aspartate and prolonged intermittent hemodialysis, leading to a remarkable outcome. Hepatitis A is usually self-limited and vaccine-preventable; supportive care is often sufficient for treatment, and chronic infection or chronic liver disease rarely develops. However, fulminant hepatitis, although rare, can be very challenging to manage as in the case of our patient.
Keywords
How to Cite
References
Abutaleb A, Kottilil S. Hepatitis A. Gastroenterol Clin N Am. 2020;49(2):191–9. 10.1016/j.gtc.2020.01.002
Jeong S-H, Lee H-S. Hepatitis A: Clinical manifestations and management. Intervirology. 2010;53(1):15–9. 10.1159/000252779
Iorio N, John S. Hepatitis A. Treasure Island, FL: StatPearls Publishing; 2022.
Bernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJ, Auzinger G, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol. 2013;59(1):74–80. 10.1016/j.jhep.2013.02.010
Shammout R, Alhassoun T, Rayya F. Acute liver failure due to hepatitis A virus. Case Rep Gastroenterol. 2021;15(3):927–32. 10.1159/000514393
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology. 2021;75(5):1194–203. 10.1002/hep.32255
Butterworth RF. L-Ornithine L-aspartate (LOLA) for the treatment of hepatic encephalopathy in cirrhosis: Novel insights and translation to the clinic. Drugs. 2019;79(S1):1–3. 10.1007/s40265-018-1021-4
Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Efficacy of L-ornithine L-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301–13. 10.1016/j.jceh.2018.05.004
Kircheis G, Lüth S. Pharmacokinetic and pharmacodynamic properties of L-Ornithine L-aspartate (LOLA) in hepatic encephalopathy. Drugs. 2019;79(S1):23–9. 10.1007/s40265-018-1023-2
Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses of N-acetyl cysteine. Cell J. 2017;19(1):11–7. 10.22074/cellj.2016.4872
Walayat S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: An updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235–240. 10.20524/aog.2021.0571
Oe S. Hepatitis A complicated with acute renal failure and high hepatocyte growth factor: A case report. World J Gastroenterol. 2015;21(32):9671. 10.3748/wjg.v21.i32.9671
Gupta S, Fenves AZ, Hootkins R. The role of RRT in hyperammonemic patients. Clin J Am Soc Nephrol. 2016;11(10):1872–78. 10.2215/cjn.01320216
Cohen PG. The hypokalemic, bowel, bladder, headache relationship; a new syndrome. the role of the potassium ammonia Axis. Med Hypotheses. 1984;15(2):135–40. 10.1016/0306-9877(84)90118-x
Kamboj M, Kazory A. Expanding the boundaries of combined renal replacement therapy for non-renal indications. Blood Purific. 2018;47(1–3):69–72. 10.1159/000493179
Alfadhel M, Mutairi FA, Makhseed N, Jasmi FA, Al-Thihli K, Al-Jishi E, et al. “Guidelines for acute management of hyperammonemia in the Middle East region.” Ther Clin Risk Manag 2016; 12: 479–87. 10.2147/TCRM.S93144
Cardoso F S, Gottfried M, Tujjos S, Olson JC, Karvellas CJ, US Acute Liver Failure Study Group. “Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.” Hepatology. 2018;67(2): 711–20. 10.1002/hep.29488
Copyright and licence
Copyright (c) 2023 Nourhane Obeid, Khaled H. Soukarieh, Jessy G. Fadel, Rayyan M. Wazzi-Mkahal, Marianne A. Alwan, Jessica J. Fakhir, Paul W. Rassam, Najat I. Joubran, Mona H. Hallak
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
